UBS Group
GOSS icon

UBS Group’s Gossamer Bio GOSS Stock Holding History

UBS Group’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$620K Buy
1,883,583
+112,202
+6% +$176K ﹤0.01% 5918
2025
Q4 		$5.49M Sell
1,771,381
-998,665
-36% -$2.85M ﹤0.01% 3936
2025
Q3 		$7.29M Buy
2,770,046
+2,457,304
+786% +$5.42M ﹤0.01% 3637
2025
Q2 		$385K Buy
312,742
+92,470
+42% +$101K ﹤0.01% 6232
2025
Q1 		$242K Buy
220,272
+201,234
+1,057% +$233K ﹤0.01% 6409
2024
Q4 		$17.2K Sell
19,038
-130,797
-87% -$112K ﹤0.01% 7977
2024
Q3 		$148K Buy
149,835
+149,790
+332,867% +$144K ﹤0.01% 6081
2024
Q2 		$41 Sell
45
-5,480
-99% -$4.1K ﹤0.01% 9250
2024
Q1 		$6.52K Sell
5,525
-18,491
-77% -$20.4K ﹤0.01% 7454
2023
Q4 		$21.9K Buy
24,016
+22,016
+1,101% +$16.3K ﹤0.01% 7053
2023
Q3 		$1.67K Sell
2,000
-175,393
-99% -$202K ﹤0.01% 7862
2023
Q2 		$213K Buy
177,393
+3,406
+2% +$4.24K ﹤0.01% 5435
2023
Q1 		$219K Sell
173,987
-1,556,319
-90% -$2.98M ﹤0.01% 5318
2022
Q4 		$3.75M Buy
1,730,306
+1,699,439
+5,506% +$14M ﹤0.01% 2770
2022
Q3 		$370K Sell
30,867
-82,958
-73% -$1.03M ﹤0.01% 4591
2022
Q2 		$953K Sell
113,825
-69,973
-38% -$542K ﹤0.01% 3781
2022
Q1 		$1.6M Buy
183,798
+18,370
+11% +$177K ﹤0.01% 3652
2021
Q4 		$1.87M Buy
165,428
+103,453
+167% +$1.23M ﹤0.01% 3793
2021
Q3 		$779K Buy
61,975
+49,538
+398% +$456K ﹤0.01% 4396
2021
Q2 		$101K Sell
12,437
-68,549
-85% -$594K ﹤0.01% 5870
2021
Q1 		$749K Buy
80,986
+80,583
+19,996% +$812K ﹤0.01% 4533
2020
Q4 		$4K Buy
403
+287
+247% +$2.83K ﹤0.01% 7909
2020
Q3 		$1K Buy
+116
New +$1.54K ﹤0.01% 7790
2020
Q2 		– Sell
-4,077
Closed -$41K – 8099
2020
Q1 		$41K Sell
4,077
-25,447
-86% -$332K ﹤0.01% 5984
2019
Q4 		$461K Sell
29,524
-27,330
-48% -$550K ﹤0.01% 4908
2019
Q3 		$955K Buy
56,854
+6,047
+12% +$120K ﹤0.01% 4002
2019
Q2 		$1.13M Buy
+50,807
New +$972K ﹤0.01% 3659

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

UBS Group's GOSS Position: Q1 2026 in Review

UBS Group increased its Gossamer Bio (GOSS) stake by 6.3% in Q1 2026, buying an estimated $176K and bringing the position to 1,883,583 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #5918.

UBS Group first reported a position in GOSS in Q2 2019 and has held it in 27 quarters since. The position peaked at $7.29M in Q3 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • UBS Group held 1,883,583 shares of Gossamer Bio worth $620K as of Q1 2026.
  • UBS Group bought 112,202 Gossamer Bio shares in Q1 2026, an estimated $176K.
  • Gossamer Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5918 holding.
  • UBS Group first reported a position in Gossamer Bio in Q2 2019 and has held it in 27 quarters since.
  • UBS Group's Gossamer Bio position peaked at $7.29M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.